40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Informations projet

BRIGHT

N° de convention de subvention: 867873

DOI

10.3030/867873

Projet clôturé

Date de signature de la CE 26 Avril 2019

Date de début 1 Mai 2019

Date de fin 30 Septembre 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

OPTOCEUTICS APS
Denmark

Periodic Reporting for period 1 - BRIGHT (40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease)

Période du rapport: 2019-05-01 au 2019-09-30

Résumé du contexte et des objectifs généraux du projet

One of the major public health challenges worldwide is the rapidly growing number of people with dementia. More than 50 million people worldwide are living with dementia and about 70% of those are diagnosed with Alzheimer’s disease. Although a global burden – equivalent to 1% of the world's GDP – AD is particularly critical in the EU, where over 10.5 million patients live with dementia.
BRIGHT aims to develop 40 Hz flickering light therapy using novel invisible spectral flicker (ISF) that can induce brainwaves in AD patients and potentially improve cognition and potentially slow the disease progression. The light is combined in a way that the flickering is non-perceptible and thus not hindering vision or causing discomfort. The primary objective of the project is to validate the need for such a treatment, and establish the necessary partners for the clinical evaluation.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the feasibility study of Phase 1 we gathered tremendous amount of information and uncovered valuable knowledge and understanding, some of which are the following:
- User requirements addressed by subsequent new design features
- Market analysis that identified the most interesting market segment, in regards to effect, willingness and size. This sharpens our eye and approach onwards in regards to product development, strategy and IPR
- Effective and detailed national go-to-market strategy and business model to address the market segment, including supply and sales setup
- Strong partnership with key clinical partners and pilot test participants

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

With the work done in SMEi Phase 1, it is now possible to move directly forward to clinical tests, with a device at that is validated among the users, designed and optimised for regulatory approval.
Furthermore a clear plan of the implementations of the 40 Hz neuromodulation light in a business setting is prepared - Ultimately leading to potentially better health and life among the population.

Optoceutics Logo